Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432598 | 1.00 | MEN1 (0.46) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL30590331 | 1.00 | MEN1 (0.46) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL30590278 | 1.00 | MEN1 (0.46) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL30590286 | 1.00 | MEN1 (0.46) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25374317 | 0.91 | MEN1 (0.46) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL26064225 | 0.90 | MEN1 (0.58) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25432110 | 0.90 | MEN1 (0.58) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL26064226 | 0.90 | MEN1 (0.58) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL25433581 | 0.90 | RAD51 (0.45) | MEN1KMT2ARAD51KDM4EALDH1A1 | |
| SCHEMBL30590343 | 0.90 | MEN1 (0.45) | MEN1KMT2ARAD51KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |